Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 162

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 162
---
 of common stock from the Underwritten Offering, net of commissions and offering expenses

    —

    65,479

    Proceeds from issuance of common stock from the “at-the-market” offering, net of commissions and offering expenses

    —

    19,050

    Proceeds from issuance of common stock under the ESPP

    147

    366

    Proceeds from exercise of stock options

    225

    99

    Net cash provided by financing activities

    372

    84,994

    Net increase (decrease) in cash and cash equivalents

    5,704

    (11,572
    )

    Cash and cash equivalents at the beginning of the period

    15,647

    27,219

    Cash and cash equivalents at the end of the period
     
    $
    21,351

    $
    15,647

The accompanying notes are an integral part of these financial statements.

F-6

AN2 Therapeutics, Inc.

Notes to Financial Statements

Note 1. Organization and Description of the BusinessDescription of BusinessAN2 Therapeutics, Inc. (the “Company”) is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The Company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (“NTM”), and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. The Company was incorporated in the state of Delaware in February 2017, began operations in November 2019, began trading on the Nasdaq Global Select Market on March 25, 2022 under the symbol “ANTX”, and is based in Menlo Park, California.Since launching operations in November 2019, the Company has devoted substantially all of its resources to performing research and development activities, including with respect to its initial product candidate, epetraborole, and other product candidates, business planning and restructuring, hiring personnel, raising capital, and providing general and administrative support for these operations.Initial Public OfferingOn March 24, 2022, the Company’s registration statement on Form S-1 (File No. 333-263295) relating to its initial public offering (“IPO”) of common stock became effective. The IPO closed on March 29, 2022, at which time the Company issued an aggregate of 4